About
ADC, Monoclonal Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
638
By Phase
PHASE3: 1PHASE1: 1
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06177041Lead Sponsor
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
PHASE3Recruiting
486 participants
Started: Dec 25, 2023 · Completed: Apr 11, 2027
NCT04894825Lead Sponsor
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
PHASE1Recruiting
152 participants
Started: Jun 11, 2021 · Completed: Dec 30, 2024
Locations (1)
Headquarters
Beijing, China
Map
Loading map...